RHINOstic Automated Nasal swabs work with a variety of automated decappers to create a hands-free diagnostics workflow. Credit: Business Wire.

Rhinostics has secured approval from Health Canada for the commercialisation of its RHINOstic Automated Nasal Swab for medically supervised collection or self-collection for adults.

The patent-pending nasal swab received Covid-19 medical device authorisation for importation or sale from the authority. This will enable Rhinostics to start delivering RHINOstic to Canadian laboratories.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Rhinostics president and CEO Cheri Walker said: “The Health Canada approval for our RHINOstic represents an important milestone in our regulatory and commercialisation strategies, validating the clinical performance of our novel nasal swabs compared to flocked nasopharyngeal products.

“More importantly, any Canadian involved in swab sample collection or processing, from patient to clinician to lab technician, can now experience the positive and lasting impact of our innovative automated swab technologies.”

RHINOstic is a polypropylene-based sterile nasal swab, which comes with a cap that supports automated decapping.

Once the nasal sample is collected, the swab is placed in a tube for transport. According to the company, the hydrophobic material and lack of viral transport media (VTM) reduce reagent costs as well as leaking risks.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Rhinostics further said that up to 96 samples can be accessioned, decapped and processed into assay plates simultaneously, using a hands-free workflow process with robotic decapper and automated liquid handler.

The technology will support high-throughput workflows with little manual intervention. Laboratories will also be able to manage and process an increased number of Covid-19 tests during outbreaks, without needing to hire temporary workers.